98 related articles for article (PubMed ID: 9170150)
1. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus.
Sabbagh N; Delaporte E; Marez D; Lo-Guidice JM; Piette F; Broly F
Pharmacogenetics; 1997 Apr; 7(2):131-5. PubMed ID: 9170150
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases].
Delaporte E; Catteau B; Sabbagh N; Gosselin P; Breuillard F; Doutre MS; Broly F; Piette F; Bergoend H
Ann Dermatol Venereol; 1997; 124(2):151-6. PubMed ID: 9740825
[TBL] [Abstract][Full Text] [Related]
3. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects.
Brocvielle H; Muret P; Goydadin AC; Boone P; Broly F; Kantelip JP; Humbert P
Skin Pharmacol Appl Skin Physiol; 2003; 16(6):386-92. PubMed ID: 14528063
[TBL] [Abstract][Full Text] [Related]
4. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.
Ricart E; Taylor WR; Loftus EV; O'Kane D; Weinshilboum RM; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
Am J Gastroenterol; 2002 Jul; 97(7):1763-8. PubMed ID: 12135032
[TBL] [Abstract][Full Text] [Related]
5. [Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism].
Furet Y; Bechtel Y; Le Guellec C; Bechtel PR; Autret-Leca E; Paintaud G
Therapie; 2002; 57(5):427-31. PubMed ID: 12611196
[TBL] [Abstract][Full Text] [Related]
6. The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis.
Yee J; Kim SM; Han JM; Lee N; Yoon HY; Gwak HS
Sci Rep; 2020 Feb; 10(1):3658. PubMed ID: 32107440
[TBL] [Abstract][Full Text] [Related]
7. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.
Kumagai S; Komada F; Kita T; Morinobu A; Ozaki S; Ishida H; Sano H; Matsubara T; Okumura K
Pharm Res; 2004 Feb; 21(2):324-9. PubMed ID: 15032315
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of chronic lupus erythematosus with sulfasalazine in 18 patients: reappraisal].
Duparc A; Staumont-Sallé D; Broly F; Piette F; Delaporte E
Presse Med; 2006; 35(7-8):1138-42. PubMed ID: 16840889
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.
Wadelius M; Stjernberg E; Wiholm BE; Rane A
Pharmacogenetics; 2000 Feb; 10(1):35-41. PubMed ID: 10739170
[TBL] [Abstract][Full Text] [Related]
10. Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.
Kuhn UD; Anschütz M; Schmücker K; Schug BS; Hippius M; Blume HH
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):1-10. PubMed ID: 20040334
[TBL] [Abstract][Full Text] [Related]
11. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.
Chen M; Xia B; Chen B; Guo Q; Li J; Ye M; Hu Z
Can J Gastroenterol; 2007 Mar; 21(3):155-8. PubMed ID: 17377643
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene.
Tanaka E; Taniguchi A; Urano W; Nakajima H; Matsuda Y; Kitamura Y; Saito M; Yamanaka H; Saito T; Kamatani N
J Rheumatol; 2002 Dec; 29(12):2492-9. PubMed ID: 12465141
[TBL] [Abstract][Full Text] [Related]
13. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
Al-Ahmad MM; Amir N; Dhanasekaran S; John A; Abdulrazzaq YM; Ali BR; Bastaki S
Ann Hum Genet; 2017 Sep; 81(5):190-196. PubMed ID: 28653770
[TBL] [Abstract][Full Text] [Related]
14. [Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping].
Goldenkova-Pavlova IV; Bruskin SA; Abdeev RM; Markarova EV; Bigvava SG; Radkevich LA; Kozhekbaeva ZhM; Glotov AS; Gra OA; Zasedatelev AS; Nasedkina TV; Kurdanov KhA; Piruzian ES
Genetika; 2006 Aug; 42(8):1143-50. PubMed ID: 17025166
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
[TBL] [Abstract][Full Text] [Related]
16. Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test.
Taja-Chayeb L; González-Fierro A; Miguez-Muñoz C; Trejo-Becerril C; Cruz-Hernandez Ede L; Cantu D; Agundez JA; Vidal-Millan S; Gutierrez O; Dueñas-González A
Pharmacogenet Genomics; 2011 Dec; 21(12):894-901. PubMed ID: 21946899
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of sulfasalazine in discoid lupus erythematosus.
Artüz F; Lenk N; Deniz N; Alli N
Int J Dermatol; 1996 Oct; 35(10):746-8. PubMed ID: 8891833
[No Abstract] [Full Text] [Related]
18. N-acetyltransferase polymorphism in patients with Behçet's disease.
Aynacioglu AS; Bozkurt A; Nacak M; Kortunay S; Tunc R; Dincel A; Kayaalp SO
Eur J Clin Pharmacol; 2001 Nov; 57(9):659-62. PubMed ID: 11791896
[TBL] [Abstract][Full Text] [Related]
19. Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupus erythematosus in a Japanese population.
Kiyohara C; Washio M; Horiuchi T; Tada Y; Asami T; Ide S; Takahashi H; Kobashi G;
Lupus; 2009 Jun; 18(7):630-8. PubMed ID: 19433464
[TBL] [Abstract][Full Text] [Related]
20. Increased genotype frequency of N-acetyltransferase 2 slow acetylation in patients with rheumatoid arthritis.
Pawlik A; Ostanek L; Brzosko I; Gawroska-Szklarz B; Brzosko M; Dabrowska-Zamojcin E
Clin Pharmacol Ther; 2002 Sep; 72(3):319-25. PubMed ID: 12235453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
